


The invention relates to the application of coordinative combinations in medicine, namely to the use of (μ-aqua)bis(μ-trichloroacetato)-tri(aqua)cobalt-aqua-bis(trichloroacetato)cobalt monohydrate as inhibitor of human myeloid leukemia.

Summary of the invention consists in that as inhibitor of human myeloid leukemia is claimed (μ-aqua)-bis(μ-trichloroacetato)-tri(aqua)cobalt-aqua-bis(trichloroacetato)cobalt monohydrate of the formula:



The result of the invention consists in the establishment at the known (μ-aqua)-bis(μ-trichloroacetato)-tri(aqua)cobalt-aqua-bis(trichloroacetato)cobalt monohydrate of the anticancer activity, exceeding 1,25...1,35 times the analogous characteristics of the dimeric trihydrate of aquaethylenediaminetetraacetatobismuthate(III) of 1,6-dinitrotetraamminecobalt(III) and dehydrate of ethylenediaminetetraacetatobismuthate(III) of oxalatotetraamminecobalt(III) (of the analogue).

Claims: 1